Cross-Sectional Multicenter Biomonitoring Study on Genotoxicity and Oxidative DNA Damage in Oncology Healthcare Workers from Seven Italian Hospitals
Abstract
1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. Analysis of Workplace and Personal Monitoring Data
2.3. Direct/Oxidative DNA Damage—Fpg Comet Assay
2.4. Statistical Methods
3. Results
3.1. Study Population
3.2. Workplace and Personal Monitoring (Data Analysis)
3.3. Fpg-Comet Assay (Direct and Oxidative DNA Damage)
3.4. Association Between Fpg-Comet and BMCyt Assay
4. Discussion
5. Conclusions
- Better inform and form workers on the potential risk of these drug mixtures.
- Raise awareness and assess risk perception, ensuring that all staff understand the dangers associated with handling antineoplastic drugs and regularly checking how well they perceive these risks.
- Follow guidelines by adhering to official protocols and safety procedures designed to protect workers from hazardous drug exposure.
- Use PPE correctly to shield oneself from contact with dangerous substances.
- Minimize exposure and contamination by taking all necessary precautions and to prevent the spread of contamination to surfaces and clothing in the workplace.
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| AD | Antineoplastic drug |
| GEM | Gemcitabine |
| IFO | Ifosfamide |
| CP | Cyclophosphamide |
| 5-FU | 5-Fluorouracil |
| Pt | Platinum compound |
| IARC | International Agency for Research on Cancer |
| NIOSH | National Institute for Occupational Safety and Health |
| ROS | Reactive Oxygen Species |
| MN | Micronucleus |
| NB | Nuclear Bud |
| BE | Broken Egg |
| NTP | National Toxicology Program |
| HPLC | High-Performance Liquid Chromatography |
| UHPLC | Ultra High-Performance Liquid Chromatography |
| GC | Gas Chromatography |
| ICP | Inductively Coupled Plasma |
| MS | Mass Spectrometry |
| BMCyt | Buccal Micronucleus Cytome |
| FPG | Formamido-pyrimidine DNA glycosylase- |
| ENDOIII | Endonuclease III |
| HIPEC | Hyperthermic Intraperitoneal Chemotherapy |
| PIPAC | Pressurized Intraperitoneal Aerosol Chemotherapy |
| LOD | Limit of Detection |
| PBS | Phosphate-Buffered Saline |
| EDTA | Ethylenediaminetetraacetic Acid |
| DMSO | Dimethyl Sulfoxide |
| NMA | Normal Melting Agarose |
| LMA | Low Melting Agarose |
| TL | Tail Length |
| TM | Tail Moment |
| CI | Confidence Interval |
| Buff | Buffer |
| Enz | Enzyme |
References
- National Toxicology Program (NTP). NTP Monograph on the Systematic Review of Occupational Exposure to Cancer Chemotherapy Agents and Adverse Health Outcomes. NTP Monogr. 2019, 5, 1. [Google Scholar] [CrossRef]
- Ladeira, C.; Møller, P.; Giovannelli, L.; Gajski, G.; Haveric, A.; Bankoglu, E.E.; Azqueta, A.; Gerić, M.; Stopper, H.; Cabêda, J.; et al. The Comet Assay as a Tool in Human Biomonitoring Studies of Environmental and Occupational Exposure to Chemicals—A Systematic Scoping Review. Toxics 2024, 12, 270. [Google Scholar] [CrossRef]
- Gianfredi, V.; Nucci, D.; Fatigoni, C.; Salvatori, T.; Villarini, M.; Moretti, M. Extent of Primary DNA Damage Measured by the Comet Assay in Health Professionals Exposed to Antineoplastic Drugs: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2020, 17, 523. [Google Scholar] [CrossRef]
- Huang, X.; Gao, C.; Cai, W.; Tao, Y.; Zhong, X.; Liu, H.; Hong, X.; Ding, X.; Lu, H.; Lai, W.; et al. Effect of Occupational Exposure to Antineoplastic Drugs on DNA Damage in Nurses: A Cross-Sectional Study. Occup. Environ. Med. 2022, 79, 253–258. [Google Scholar] [CrossRef]
- Sasaki, M.; Dakeishi, M.; Hoshi, S.; Ishii, N.; Murata, K. Assessment of DNA Damage in Japanese Nurses Handling Antineoplastic Drugs by the Comet Assay. J. Occup. Health 2008, 50, 7–12. [Google Scholar] [CrossRef]
- Huang, H.; Gu, Y.; Liu, S.; Hu, S.; Zhong, X.; Huang, Y.; Peng, J.; Huang, X. The Meta-Analysis of Cytogenetic Biomarkers as an Assessment of Occupational Risk for care Workers Exposed to Antineoplastic Drugs. Int. Arch. Occup. Environ. Health 2023, 96, 785–796. [Google Scholar] [CrossRef]
- Collins, A.; Moller, P.; Gajski, G.; Vodenkova, S.; Abdulwahed, A.; Anderson, D.; Bankoglu, E.E.; Bonassi, S.; Boutet-Robinet, E.; Brunborg, G.; et al. Measuring DNA Modifications with the Comet Assay: A Compendium of Protocols. Nat. Protoc. 2023, 18, 929–989. [Google Scholar] [CrossRef]
- Collins, A.R.; Duthie, S.J.; Dobson, V.L. Direct Enzymic Detection of Endogenous Oxidative Base Damage in Human Lymphocyte DNA. Carcinogenesis 1993, 14, 1733–1735. [Google Scholar] [CrossRef]
- Conklin, K.A. Chemotherapy-Associated Oxidative Stress: Impact on Chemotherapeutic Effectiveness. Integr. Cancer Ther. 2004, 3, 294–300. [Google Scholar] [CrossRef]
- Yang, H.; Villani, R.M.; Wang, H.; Simpson, M.J.; Roberts, M.S.; Tang, M.; Liang, X. The Role of Cellular Reactive Oxygen Species in Cancer Chemotherapy. J. Exp. Clin. Cancer Res. 2018, 37, 266. [Google Scholar] [CrossRef]
- Nakamura, H.; Takada, K. Reactive Oxygen Species in Cancer: Current Findings and Future Directions. Cancer Sci. 2021, 112, 3945–3952. [Google Scholar] [CrossRef]
- Ursini, C.L.; Omodeo-Salè, E.; Di Gennaro, G.; Buresti, G.; Fresegna, A.M.; Ciervo, A.; Gentile, M.; Maiello, R.; Beltramini, S.; Gaggero, D.; et al. Buccal Micronucleus Cytome Assay to Evaluate Cyto-Genotoxic Effects of Occupational Exposure to Antineoplastic Drugs: Application on a Large Sample Size of Workers Furnished by an Italian Network of Oncological Hospitals. Arch. Toxicol. 2025, 99, 3429–3441. [Google Scholar] [CrossRef]
- Luzhna, L.; Kathiria, P.; Kovalchuk, O. Micronuclei in Genotoxicity Assessment: From Genetics to Epigenetics and Beyond. Front. Genet. 2013, 4, 131. [Google Scholar] [CrossRef]
- Fenech, M.; Kirsch-Volders, M.; Natarajan, A.T.; Surralles, J.; Crott, J.W.; Parry, J.; Norppa, H.; Eastmond, D.A.; Tucker, J.D.; Thomas, P. Molecular Mechanisms of Micronucleus, Nucleoplasmic Bridge and Nuclear Bud Formation in Mammalian and Human Cells. Mutagenesis 2011, 26, 125–132. [Google Scholar] [CrossRef]
- Sottani, C.; Grignani, E.; Cornacchia, M.; Negri, S.; Cuna, F.S.R.D.; Cottica, D.; Bruzzese, D.; Severi, P.; Strocchi, D.; Verna, G.; et al. Occupational Exposure Assessment to Antineoplastic Drugs in Nine Italian Hospital Centers over a 5-Year Survey Program. Int. J. Environ. Res. Public Health 2022, 19, 8601. [Google Scholar] [CrossRef]
- Cavallo, D.; Ursini, C.L.; Setini, A.; Chianese, C.; Cristaudo, A.; Iavicoli, S. DNA Damage and TNFalpha Cytokine Production in Hairdressers with Contact Dermatitis. Contact Dermat. 2005, 53, 125–129. [Google Scholar] [CrossRef]
- Collins, A.R. Measuring Oxidative Damage to DNA with Comet Assay. Biochim. Biophys. Acta 2014, 1840, 794–800. [Google Scholar] [CrossRef]
- Cavallo, D.; Tranfo, G.; Ursini, C.L.; Fresegna, A.M.; Ciervo, A.; Maiello, R.; Paci, E.; Pigini, E.; Gherardi, M.; Gatto, M.P.; et al. Biomarkers of Early Genotoxicity and Oxidative Stress for Occupational Risk Assessment of Exposure to Styrene in the Fibreglass Reinforced Plastic Industry. Toxicol. Lett. 2018, 298, 53–59. [Google Scholar] [CrossRef]
- Ndaw, S.; Hanser, O.; Kenepekian, V.; Vidal, M.; Melczer, M.; Remy, A.; Robert, A.; Bakrin, N. Occupational Exposure to Platinum Drugs during Intraperitoneal Chemotherapy. Biomonitoring and Surface Contamination. Toxicol. Lett. 2018, 298, 171–176. [Google Scholar] [CrossRef]
- Roussin, F.; Taibi, A.; Canal-Rafn, M.; Cantournet, L.; Durand-Fontanier, S.; Druet-Cabanac, M.; El Balkhi, S.; Maillan, G. Assessment of Workplace Environmental Contamination and Occupational Exposure to Cisplatin and Doxorubicin Aerosols during Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy. Eur. J. Surg. Oncol. 2021, 47, 2939–2947. [Google Scholar] [CrossRef]
- Delafoy, C.; Benoist, H.; Patin, A.; Vasseur, M.; Guillouet, S.; Eveno, C.; Guilloit, J.M.; Odou, P.; Simon, N.; Saint-Lorant, G. Knowledge and Practices about Safe Handling Regarding the Risk of Exposure to Antineoplastic Drugs for Caregivers in Compounding Units and in Operating Rooms Performing HIPEC/PIPAC. J. Oncol. Pharm. Pract. 2023, 29, 1628–1636. [Google Scholar] [CrossRef]
- Rekhadevi, P.V.; Sailaja, N.; Chandrasekhar, M.; Mahboob, M.; Rahman, M.F.; Grover, P. Genotoxicity Assessment in Oncology Nurses Handling Anti-Neoplastic Drugs. Mutagenesis 2007, 22, 395–401. [Google Scholar] [CrossRef]
- Ursini, C.L.; Cavallo, D.; Colombi, A.; Giglio, M.; Marinaccio, A.; Iavicoli, S. Evaluation of Early DNA Damage in Care Workers Handling Antineoplastic Drugs. Int. Arch. Occup. Environ. Health 2006, 80, 134–140. [Google Scholar] [CrossRef]
- Buschini, A.; Villarini, M.; Feretti, D.; Mussi, F.; Dominici, L.; Zerbini, I.; Moretti, M.; Ceretti, E.; Bonfiglioli, R.; Carrieri, M.; et al. Multicentre Study for the Evaluation of Mutagenic/Carcinogenic Risk in Nurses Exposed to Antineoplastic Drugs: Assessment of DNA Damage. Occup. Environ. Med. 2013, 70, 789–794. [Google Scholar] [CrossRef]
- Ladeira, C.; Viegas, V.; Pádua, M.; Carolino, E.; Gomes, M.C.; Brito, M. Relation between DNA Damage Measured by Comet Assay and OGG1 Ser326Cys Polymorphism in Antineoplastic Drugs Biomonitoring. AIMS Genet. 2015, 2, 204–218. [Google Scholar] [CrossRef][Green Version]
- Connor, T.H.; DeBord, D.G.; Pretty, J.R.; Oliver, M.S.; Roth, T.S.; Lees, P.S.; Krieg, E.F., Jr.; Rogers, B.; Escalante, C.P.; Toennis, C.A.; et al. Evaluation of Antineoplastic Drug Exposure of Health Care Workers at Three University-Based US Cancer Centers. J. Occup. Environ. Med. 2010, 52, 1019–1027. [Google Scholar] [CrossRef]
- Rombaldi, F.; Cassini, C.; Salvador, M.; Saffi, J.; Erdtmann, B. Occupational Risk Assessment of Genotoxicity and Oxidative Stress in Workers Handling Anti-Neoplastic Drugs during a Working Week. Mutagenesis 2009, 24, 143–148. [Google Scholar] [CrossRef]
- Mahboob, M.; Rahman, M.F.; Rekhadevi, P.V.; Sailaja, N.; Balasubramanyam, A.; Prabhakar, P.V.; Singh, S.P.; Utkarsh, A.; Reddy, G.; Rao, S.; et al. Monitoring of Oxidative Stress in Nurses Occupationally Exposed to Antineoplastic Drugs. Toxicol. Int. 2012, 19, 20–24. [Google Scholar] [CrossRef]
- Gómez-Oliván, L.M.; Miranda-Mendoza, G.D.; Cabrera-Galeana, P.A.; Galar-Martínez, M.; Islas-Flores, H.; Sanjuan-Reyes, N.; Neri-Cruz, N.; García-Medina, S. Oxidative Stress Induced in Nurses by Exposure to Preparation and Handling of Antineoplastic Drugs in Mexican Hospitals: A Multicentric Study. Oxidative Med. Cell. Longev. 2014, 2014, 858604. [Google Scholar] [CrossRef]
- Mrdjanović, J.; Šolajić, S.; Srdenović-Conić, B.; Bogdanović, V.; Dea, K.J.; Kladar, N.; Jurišić, V. The Oxidative Stress Parameters as Useful Tools in Evaluating the DNA Damage and Changes in the Complete Blood Count in Hospital Workers Exposed to Low Doses of Antineoplastic Drugs and Ionizing Radiation. Int. J. Environ. Res. Public Health 2021, 18, 8445. [Google Scholar] [CrossRef]
- Santos, A.N.; Oliveira, R.J.; Pessatto, L.R.; Gomes, R.D.S.; Freitas, C.A.F. Biomonitoring of Pharmacists and Nurses at Occupational Risk from Handling Antineoplastic Agents. Int. J. Pharm. Pract. 2020, 28, 506–511. [Google Scholar] [CrossRef] [PubMed]
- Mateuca, R.; Lombaert, N.; Aka, P.V.; Decordier, I.; Kirsch-Volders, M. Chromosomal Changes: Induction, Detection Methods and Applicability in Human Biomonitoring. Biochimie 2006, 88, 1515–1531. [Google Scholar] [CrossRef]



| (A) | |||||||||
| Sample | Gender | Smoking Habit | Age | Job Seniority | |||||
| Males | Females | Yes | No | Former | Mean ± SD | [Range] | Mean (Years ± SD) | [Range] | |
| N (%) | N (%) | N (%) | N (%) | N (%) | |||||
| Hospital A | 11 (18.6) | 48 (81.4) | 6 (10.0) | 44 (73.3) | 10 (16.7) | 41.24 ± 10.23 | [23–65] | 12.55 ± 9.56 | [0.3–34] |
| Hospital B | 4 (19.0) | 17 (81.0) | 4 (21.1) | 14 (73.7) | 1 (5.3) | 36.57 ± 8.39 | [25–53] | 7.25 ± 8.20 | [1–25] |
| Hospital C | 12 (20.0) | 48 (80.0) | 7 (14.0) | 41 (82.0) | 2 (4.0) | 46.68 ± 11.47 | [26–65] | 10.23 ± 9.29 | [0.1–30] |
| Hospital D | 20 (28.2) | 51 (71.8) | 3 (4.3) | 66 (95.7) | 0 (0.0) | 44.00± 11.46 | [22–63] | 10.73 ± 8.90 | [0.2–28] |
| Hospital E | 19 (45.2) | 23 (54.8) | 18 (43.9) | 18 (43.9) | 5 (12.2) | 41.78 ± 9.01 | [26–65] | 8.05 ± 5.41 | [1–18] |
| Hospital F | 16 (18.0) | 73 (82.0) | 11 (14.7) | 55 (73.3) | 9 (12.0) | 41.08 ± 11.38 | [25–66] | 6.27 ± 7.47 | [0.3–30] |
| Hospital G | 12 (34.3) | 23 (65.7) | 8 (25.0) | 17 (53.1) | 7 (21.9) | 40.26 ± 8.37 | [26–66] | 12.29 ± 7.11 | [0.3–26] |
| Total (N = 378) | 94 (24.9) | 283 (75.1) | 57 (16.5) | 255 (73.7) | 34 (9.8) | 42.30 ± 10.82 | [22–66] | 9.29 ± 8.45 | [0.1–34] |
| Controls (N = 164) | 46 (28.0) | 118 (72.0) | 21 (13.9) | 113 (74.8) | 17 (11.3) | 42.93 ± 10.63 | [23–65] | 7.30 ± 7.45 | [0.3–30] |
| Exposed (N = 214) | 48 (22.5) | 165 (67.5) | 36 (18.5) | 142 (72.8) | 17 (8.7) | 41.82 ± 10.96 | [22–66] | 9.51 ± 8.54 | [0.1–34] |
| Preparators (N = 58) | 26 (44.8) | 32 (55.2) | 4 (7.4) | 42 (77.8) | 8 (14.8) | 43.71 ± 11.54 | [25–66] | 9.10 ± 9.94 | [0.1–28] |
| Administrators (N = 132) | 17 (13.0) | 114 (87.0) | 27 (22.5) | 85 (70.8) | 8 (6.7) | 41.57 ± 10.45 | [22–66] | 10.28 ± 8.86 | [0.2–34] |
| Operating Room (N = 15) | 4 (26.7) | 11 (73.3) | 3 (23.1) | 9 (69.2) | 1 (7.7) | 32.67 ± 7.46 | [25–50] | 3.01 ± 1.51 | [1–6] |
| Disposal (N = 9) | 1 (11.1) | 8 (88.9) | 2 (25.0) | 6 (75.0) | 0 (0.0) | 48.56 ± 11.28 | [30–63] | 11.11 ± 10.17 | [1–30] |
| p-Value (Exp vs. Contr) | 0.220 a | 0.432 a | 0.298 c | 0.282 c | |||||
| p-Value (Different Tasks) | 0.001 a | 0.173 b | 0.002 d | 0.065 d | |||||
| * OR vs. Prep/Adm/Disposal/Contr | |||||||||
| (B) | |||||||||
| Consumption | Total (N = 378) | Controls (N = 164) | Exposed (N = 214) | p-Value | |||||
| N (%) | N (%) | N (%) | |||||||
| Alcohol | None | 167 (49.4) | 75 (47.8) | 92 (50.8) | 0.833 a | ||||
| Spirits occasionally | 61 (18.0) | 27 (17.2) | 34 (18.8) | ||||||
| Wine/beer | 51 (15.1) | 25 (15.9) | 26 (14.4) | ||||||
| Wine/beer/spirits occasionally | 59 (17.5) | 30 (19.1) | 29 (16.0) | ||||||
| Fruit | Rarely/never | 60 (17.3) | 20 (12.6) | 40 (21.4) | 0.052 a | ||||
| Once a day | 172 (49.7) | 79 (49.7) | 93 (49.7) | ||||||
| Several times a day | 114 (32.9) | 60 (37.7) | 54 (28.9) | ||||||
| Fresh Vegetables | Rarely | 31 (9.0) | 12 (7.5) | 19 (10.2) | 0.650 a | ||||
| Once a day | 160 (46.2) | 73 (45.9) | 87 (46.5) | ||||||
| Several times a day | 155 (44.8) | 74 (46.5) | 81 (43.3) | ||||||
| Grilled foods | Never and rarely | 41 (12.1) | 18 (11.6) | 23 (12.4) | 0.716 a | ||||
| Once a month | 122 (35.9) | 53 (34.2) | 69 (37.3) | ||||||
| 2–3 times/month | 134 (39.4) | 61 (39.4) | 73 (39.5) | ||||||
| More than 2–3 times/month | 43 (12.6) | 23 (14.8) | 20 (10.8) | ||||||
| DEPARTMENT/AREA | DRUG | POSITIVES % | MIN (ng/cm2) | MAX (ng/cm2) | |
|---|---|---|---|---|---|
| HOSPITAL A | Administration Ward | GEM | 10.0 | 0.0070 | 0.0740 |
| IFO | 16.7 | 0.0020 | 0.0440 | ||
| CP | 16.6 | 0.0008 | 0.1125 | ||
| 5-FU | 66.6 | 0.0140 | 0.4700 | ||
| Pt | 90.0 | 0.00001 | 0.0031 | ||
| Administration Day Hospital | GEM | 46.7 | 0.0012 | 0.8823 | |
| IFO | 0 | 0 | 0 | ||
| CP | 26.6 | 0.0036 | 0.0804 | ||
| 5-FU | 46.6 | 0.0149 | 0.0585 | ||
| Pt | 96.6 | 0.00007 | 2.7188 | ||
| Pharmacy | GEM | 38.5 | 0.002 | 0.4410 | |
| IFO | 15.4 | 0.072 | 0.7330 | ||
| CP | 12.8 | 0.002 | 1.0660 | ||
| 5-FU | 51.3 | 0.013 | 32.8130 | ||
| Pt | 100 | 0.00008 | 0.1254 | ||
| HOSPITAL B | Administration Day Hospital | GEM | 26.2 | 0.0008 | 0.13202 |
| IFO | 26.2 | 0 | 0.4265 | ||
| CP | 21.3 | 0 | 0.2760 | ||
| 5-FU | 50.8 | 0.0108 | 6.7928 | ||
| Pt | 100 | 0.00002 | 0.1644 | ||
| Pharmacy | GEM | 35.3 | 0.0040 | 1.9001 | |
| IFO | 20.6 | 0.0106 | 0.5403 | ||
| CP | 19.1 | 0.0061 | 0.1626 | ||
| 5-FU | 47.1 | 0.0106 | 1.6575 | ||
| Pt | 94.1 | 0.00001 | 0.0134 | ||
| HOSPITAL C | Administration Day hospital | GEM | 67.0 | 0.001 | 6.6555 |
| IFO | 5.0 | 0.00108 | 0.1714 | ||
| CP | 67.0 | 0.00048 | 2.8448 | ||
| 5-FU | 49.0 | 0.01400 | 8.1528 | ||
| Pt | 100 | 0.000031 | 0.3117 | ||
| Pharmacy | GEM | 22.0 | 0.0013 | 1.0398 | |
| IFO | 8.0 | 0.0013 | 1.3218 | ||
| CP | 32.0 | 0.0003 | 0.3819 | ||
| 5-FU | 60.0 | 0.0017 | 5.3373 | ||
| Pt | 100 | - | 0.06497 # | ||
| HOSPITAL D | Administration Day hospital | GEM | 100 | 0.0007 | 1162.91 |
| IFO | 28.8 | 0.0008 | 0.1741 | ||
| CP | 96.1 | 0.0003 | 143.51 | ||
| 5-FU | 92.3 | 0.0062 | 31.93 | ||
| Pt | 100 | 0.0026 | 59.71 | ||
| Pharmacy | GEM | 100 | 0.0123 | 66.0681 | |
| IFO | 61.5 | 0.0029 | 7.1297 | ||
| CP | 96.1 | 0.0031 | 127.1012 | ||
| 5-FU | 75.0 | 0.0133 | 27.97 | ||
| Pt | 59.6 | 0.00186 | 1973.93 | ||
| HOSPITAL E | Administration Day hospital | GEM | 98.2 | 0.0005 | 1.4366 |
| IFO | 96.4 | 0.0005 | 0.1440 | ||
| CP | 36.3 | 0.0002 | 0.0443 | ||
| 5-FU | 29.1 | 0.0157 | 0.67 | ||
| Pt | 100 | 0.00011 | 0.1147 | ||
| Pharmacy | GEM | 100 | 0.0011 | 1.5002 | |
| IFO | 100 | 0.0333 | 2.2638 | ||
| CP | 100 | 0.0012 | 0.4130 | ||
| 5-FU | 83.0 | 0.0137 | 2.0019 | ||
| Pt | 83.3 | 0.00235 | 0.033 | ||
| HOSPITAL F | Operating room | GEM | 6.25 | - | 0.0393 # |
| IFO | 6.25 | - | 0.04320 # | ||
| CP | 6.25 | - | 0.5157 # | ||
| 5-FU | 43.7 | 0.0006 | 5.2459 | ||
| Pt | 100 | 0.00003 | 0.00061 | ||
| Administration Day Hospital | GEM | 20 | 0.0017 | 4.317 | |
| IFO | 34.7 | 0.0024 | 0.4048 | ||
| CP | 26 | 0.0021 | 0.6753 | ||
| 5-FU | 67.4 | 0.0015 | 4.0838 | ||
| Pt | 100 | 0.00002 | 3.0997 | ||
| Pharmacy | GEM | 20 | 0.0160 | 0.2493 | |
| IFO | 50 | 0.0020 | 9.6327 | ||
| CP | 65 | 0.0024 | 1.8351 | ||
| 5-FU | 60 | 0.0033 | 1.8948 | ||
| Pt | 100 | 0.00005 | 0.082 | ||
| HOSPITAL G | Administration Day hospital | GEM | 78.7 | 0.0007 | 4.5207 |
| IFO | 15.3 | 0.002 | 0.8416 | ||
| CP | 47.3 | 0.0003 | 1.5681 | ||
| 5-FU | 56.6 | 0.0140 | 2.9344 | ||
| Pt | 100 | 0.0001 | 0.9227 | ||
| Pharmacy | GEM | 64 | 0.015 | 2.202 | |
| IFO | 64.3 | 0.003 | 0.620 | ||
| CP | 57 | 0.0014 | 0.9556 | ||
| 5-FU | 64 | 0.0142 | 49.6858 | ||
| Pt | 100 | 0.0013 | 0.0193 |
| DRUG | POSITIVES % | MIN (ng/cm2) | MAX (ng/cm2) | |
|---|---|---|---|---|
| HOSPITAL A | GEM | 53.7 | 0.0080 | 1.0534 |
| IFO | 25.0 | 0.0151 | 0.7277 | |
| CP | 21.8 | 0.0322 | 1.8061 | |
| 5-FU | 46.9 | 0.0573 | 22.269 | |
| Pt | 100 | 0.0012 | 0.0268 | |
| HOSPITAL B | GEM | 16.7 | 0.0984 | 0.1978 |
| IFO | 16.7 | 0.5301 | 1.0787 | |
| CP | 16.7 | 0.2042 | 0.4521 | |
| 5-FU | 33.3 | 0.0603 | 137.3869 | |
| Pt | 100 | 0.0001 | 0.0102 | |
| HOSPITAL C | GEM | 28.0 | 0.0062 | 7.1449 |
| IFO | 4.0 | 0.0297 | 21.1275 | |
| CP | 12.0 | 0.0073 | 0.5215 | |
| 5-FU | 72 | 0.018 | 1.2431 | |
| Pt | 72 | 0.000037 | 0.00328 | |
| HOSPITAL D | GEM | 20.6 | 0.0027 | 0.3100 |
| IFO | 2.9 | - | 0.6510 # | |
| CP | 8.8 | 0.047 | 0.5667 | |
| 5-FU | 47.0 | 0.0125 | 1.5563 | |
| Pt | 58.8 | 0.0101 | 7.2086 | |
| HOSPITAL E | GEM | 57.1 | 0.0011 | 23.0000 |
| IFO | 57.1 | 0.0017 | 29.005 | |
| CP | 52.4 | 0.0012 | 0.2745 | |
| 5-FU | 52.4 | 0.0580 | 4.6829 | |
| Pt | 100 | 0.0001 | 0.0088 | |
| HOSPITAL F | GEM | 39.2 | 0.0047 | 52.8507 |
| IFO | 11.8 | 0.011 | 1.8634 | |
| CP | 15.7 | 0.7773 | 10.4180 | |
| 5-FU | 35.3 | 0.0586 | 6.9453 | |
| Pt | 100 | 0.00016 | 0.2286 | |
| HOSPITAL G | GEM | 30.0 | 0.0042 | 0.0927 |
| IFO | 0 | 0 | 0 | |
| CP | 0 | 0 | 0 | |
| 5-FU | 50.0 | 0.0117 | 2.0687 | |
| Pt | 33.3 | 0.0001 | 0.0222 |
| Tail DNA% | TM | TL | %Comets | %Apoptotic Cells | |
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| Controls (N = 164) | 15.88 ± 3.44 | 4.33 ± 1.28 | 23.72 ± 5.18 | 21.56 ± 3.83 | 1.51 ± 1.35 |
| Exposed (N = 214) | 19.44 ± 4.51 | 6.06 ± 1.78 | 29.51 ± 6.53 | 22.49 ± 3.66 | 1.56 ± 1.26 |
| Prep. (N = 58) | 18.65 ± 4.20 | 5.55 ± 1.67 | 28.70 ± 6.31 | 22.32 ± 3.09 | 1.28 ± 0.59 |
| Admin. (N = 132) | 20.04 ± 4.74 | 6.38 ± 1.80 | 30.36 ± 6.59 | 22.50 ± 3.92 | 1.74 ± 1.49 |
| OR (N = 15) | 17.85 ± 3.57 | 5.67 ± 1.47 | 27.54 ± 6.08 | 21.90 ± 2.44 | 1.00 ± 0.16 |
| Disposal (N = 9) | 18.42 ± 3.29 | 5.47 ± 1.88 | 25.67 ± 5.87 | 24.36 ± 4.63 | 1.69 ± 1.24 |
| p-Value (Exp vs. Contr) | <0.001 c | <0.001 c | <0.001 c | <0.001 c | 0.044 c |
| p-Value (Different tasks) | <0.001 d | <0.001 d | <0.001 d | 0.002 d | 0.165 d |
| * Contr vs. Prep/Adm | * Prep vs. Adm | * Contr vs. Prep/Adm | * Contr vs. Prep/Adm |
| Biomarker | Independent Variables | Unstandardised B | 95% CI | Standardised Beta | p-Value | |
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Tail DNA% | Age | 0.001 | −0.040 | 0.041 | 0.001 | 0.979 |
| Gender a | 0.037 | −0.956 | 1.031 | 0.004 | 0.941 | |
| Smoking habits b | 0.541 | −0.040 | 1.122 | 0.091 | 0.068 | |
| Exposure c | 3.590 | 2.702 | 4.477 | 0.397 | <0.001 | |
| Tail DNA% enz | Age | 0.020 | −0.027 | 0.067 | 0.040 | 0.406 |
| Gender | 0.380 | −0.763 | 1.523 | 0.031 | 0.513 | |
| Smoking habits | 0.510 | −0.158 | 1.178 | 0.071 | 0.134 | |
| Exposure | 5.275 | 4.254 | 6.296 | 0.484 | <0.001 | |
| Oxidative damage | Age | 0.020 | −0.015 | 0.055 | 0.060 | 0.256 |
| Gender | 0.361 | −0.483 | 1.205 | 0.045 | 0.401 | |
| Smoking habits | −0.047 | −0.541 | 0.446 | −0.010 | 0.850 | |
| Exposure | 1.689 | 0.935 | 2.443 | 0.234 | <0.001 | |
| Tail Moment | Age | 0.004 | −0.012 | 0.020 | 0.023 | 0.624 |
| Gender | −0.125 | −0.509 | 0.259 | −0.030 | 0.523 | |
| Smoking habits | 0.078 | −0.147 | 0.302 | 0.032 | 0.497 | |
| Exposure | 1.790 | 1.447 | 2.133 | 0.489 | <0.001 | |
| Tail Length | Age | 0.011 | −0.049 | 0.071 | 0.018 | 0.722 |
| Gender | −0.556 | −2.019 | 0.908 | −0.037 | 0.456 | |
| Smoking habits | 0.390 | −0.466 | 1.246 | 0.044 | 0.371 | |
| Exposure | 5.749 | 4.442 | 7.057 | 0.427 | <0.001 | |
| %Comets | Age | 0.040 | 0.003 | 0.076 | 0.113 | 0.035 |
| Gender | −0.521 | −1.414 | 0.371 | −0.061 | 0.251 | |
| Smoking habits | −0.719 | −1.241 | −0.197 | −0.145 | 0.007 | |
| Exposure | 0.782 | −0.015 | 1.579 | 0.103 | 0.055 | |
| %Apoptotic cells | Age | 0.011 | −0.002 | 0.024 | 0.086 | 0.108 |
| Gender | −0.235 | −0.551 | 0.081 | −0.078 | 0.144 | |
| Smoking habits | −0.361 | −0.546 | −0.176 | −0.204 | <0.001 | |
| Exposure | 0.099 | −0.183 | 0.381 | 0.037 | 0.490 | |
| Independent Variables | Coefficient (β) | Odds Ratio (OR) | 95% CI | p-Value | |
|---|---|---|---|---|---|
| Lower | Upper | ||||
| Intercept | −1.514 | 0.220 | <0.001 | ||
| Female | Ref | ||||
| Male | 0.064 | 1.066 | 0.642 | 1.772 | 0.804 |
| Non-smoker | Ref | ||||
| Former smoker | 0.247 | 1.280 | 0.605 | 2.709 | 0.519 |
| Smoker | −0.058 | 0.944 | 0.514 | 1.734 | 0.852 |
| Age | 0.012 | 1.012 | 0.991 | 1.033 | 0.267 |
| Unexposed | Ref | ||||
| Exposed | 0.964 | 2.623 | 1.654 | 4.161 | <0.001 |
| Variables | Total Sample (r, p) | Controls (r, p) | Exposed (r, p) |
|---|---|---|---|
| Age—tail DNA % | −0.020, p = 0.698 | −0.012, p = 0.884 | 0.006, p = 0.932 |
| Age—Oxidative damage (tail DNA%enz-tail DNA%) | 0.036, p = 0.489 | −0.021, p = 0.787 | 0.065, p = 0.347 |
| Age—Tail Moment | −0.013, p = 0.802 | 0.032, p = 0.687 | 0.002, p = 0.975 |
| Age—Tail Length | −0.009, p = 0.861 | 0.034, p = 0.667 | 0.002, p = 0.972 |
| Variables | Total Sample (r, p) | Controls (r, p) | Exposed (r, p) |
|---|---|---|---|
| ‰MN—% DNA tail buffer | 0.151, p = 0.005 | 0.091, p = 0.268 | 0.048, p = 0.504 |
| ‰MN—% DNA tail enz-%tail DNAbuff | 0.088, p = 0.100 | 0.009, p = 0.914 | 0.033, p = 0.647 |
| ‰MN—Tail Moment | 0.177, p = 0.001 | 0.038, p = 0.643 | 0.067, p = 0.345 |
| ‰MN—Tail Length | 0.146, p = 0.007 | −0.071, p = 0.387 | 0.061, p = 0.392 |
| ‰(MN + NB + BE)—% DNA tail buff | 0.031, p = 0.563 | 0.070, p = 0.394 | −0.121, p = 0.089 |
| ‰(MN + NB + BE)—% DNAtail enz-%DNAtail buf buff | 0.063, p = 0.240 | 0.040, p = 0.621 | −0.001, p = 0.991 |
| ‰(MN + NB + BE)—Tail Moment | 0.087, p = 0.103 | 0.043, p = 0.597 | −0.043, p = 0.550 |
| ‰(MN + NB + BE)—Tail Length | 0.073, p = 0.170 | −0.010, p = 0.898 | −0.027, p = 0.702 |
| ‰ Cells Condensed Chromatin—%Apoptotic cells | 0.026, p = 0.598 | 0.010, p = 0.899 | 0.041, p = 0.564 |
| ‰Total Anomalies—%tail DNA | 0.036, p = 0.505 | 0.080 p = 0.333 | −0.124 p = 0.083 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Ursini, C.L.; Di Gennaro, G.; Buresti, G.; Maiello, R.; Fresegna, A.M.; Ciervo, A.; Gentile, M.; Di Basilio, V.; Beltramini, S.; Gaggero, D.; et al. Cross-Sectional Multicenter Biomonitoring Study on Genotoxicity and Oxidative DNA Damage in Oncology Healthcare Workers from Seven Italian Hospitals. J. Xenobiot. 2026, 16, 12. https://doi.org/10.3390/jox16010012
Ursini CL, Di Gennaro G, Buresti G, Maiello R, Fresegna AM, Ciervo A, Gentile M, Di Basilio V, Beltramini S, Gaggero D, et al. Cross-Sectional Multicenter Biomonitoring Study on Genotoxicity and Oxidative DNA Damage in Oncology Healthcare Workers from Seven Italian Hospitals. Journal of Xenobiotics. 2026; 16(1):12. https://doi.org/10.3390/jox16010012
Chicago/Turabian StyleUrsini, Cinzia Lucia, Giorgia Di Gennaro, Giuliana Buresti, Raffaele Maiello, Anna Maria Fresegna, Aureliano Ciervo, Marco Gentile, Virginia Di Basilio, Sabrina Beltramini, Daniela Gaggero, and et al. 2026. "Cross-Sectional Multicenter Biomonitoring Study on Genotoxicity and Oxidative DNA Damage in Oncology Healthcare Workers from Seven Italian Hospitals" Journal of Xenobiotics 16, no. 1: 12. https://doi.org/10.3390/jox16010012
APA StyleUrsini, C. L., Di Gennaro, G., Buresti, G., Maiello, R., Fresegna, A. M., Ciervo, A., Gentile, M., Di Basilio, V., Beltramini, S., Gaggero, D., Rigamonti, N., Maccari, E., Zorzetto, G., Maiolino, P., Di Filippo, P., Bilancio, M. C., Baldo, P., Martinello, V., Di Mattia, A., ... Cavallo, D. (2026). Cross-Sectional Multicenter Biomonitoring Study on Genotoxicity and Oxidative DNA Damage in Oncology Healthcare Workers from Seven Italian Hospitals. Journal of Xenobiotics, 16(1), 12. https://doi.org/10.3390/jox16010012

